Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIDOZALAM HYDROCHLORIDE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Midazolam hydrochloride is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal transmission. This produces sedative, anxiolytic, amnestic, and anticonvulsant effects.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Sedation (preoperative, procedural, and intensive care unit),Induction of general anesthesia,Status epilepticus (off-label)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
2.5-10 mg IV bolus for induction; 0.05-0.2 mg/kg/h IV infusion for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) 30-60 min pre-procedure.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life: 1.5-3 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity, hepatic cirrhosis (up to 20 hours), and congestive heart failure.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Midazolam is primarily metabolized by the hepatic cytochrome P450 enzyme CYP3A4 to the active metabolite 1-hydroxymidazolam (also known as alpha-hydroxymidazolam), which is further conjugated. CYP3A5 may also contribute. The drug undergoes extensive first-pass metabolism after oral administration.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal excretion of metabolites (approximately 90% as glucuronide conjugates, with less than 1% unchanged drug) and biliary/fecal excretion (approximately 5-10%).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
97-98% bound to serum albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
1.2-2.4 L/kg; increased in obesity (up to 3-5 L/kg) indicating extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 35-44% (first-pass effect); IM: 80-100%; Intranasal: 55-65%; Rectal: 40-80%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No dose adjustment required for GFR >50 m L/min. For GFR 10-50 m L/min: consider dose reduction by 25-50% due to prolonged effect. For GFR <10 m L/min: avoid use or use with extreme caution; no specific guidelines exist.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use or reduce dose by 75% with close monitoring.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
0.05-0.2 mg/kg IV (max 5 mg) for induction. For sedation: 0.15-0.2 mg/kg IM (max 10 mg) or 0.5-0.75 mg/kg oral (max 20 mg). IV infusion: 0.02-0.1 mg/kg/h titrated.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Reduce dose by 25-50% due to decreased clearance and increased sensitivity. Use lower initial doses (e.g., 1-2 mg IV) and titrate slowly.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Midazolam has a boxed warning for the risk of respiratory depression and death when used for sedation in non-intubated patients. It requires careful monitoring of respiratory function. Concomitant use with opioids or other central nervous system depressants increases the risk of profound sedation, respiratory depression, coma, and death.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression: especially with rapid IV administration or high doses; monitor oxygen saturation and respiratory rate.,Risk of hypotension and cardiac arrest, particularly in critically ill patients.,Paradoxical reactions: agitation, aggression, hallucinations (more common in children and the elderly).,Physical dependence and withdrawal syndrome with prolonged use.,Impairment of ability to drive or operate machinery.,Elderly or debilitated patients: increased sensitivity and risk of adverse effects; reduce dosage.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to midazolam or any benzodiazepine,Acute narrow-angle glaucoma (due to anticholinergic effects),Severe respiratory insufficiency (e.g., untreated sleep apnea, COPD with hypercapnia),Concomitant use with nefazodone (CYP3A4 inhibitor) in oral formulations,Myasthenia gravis (relative contraindication due to muscle relaxant effects)
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Grapefruit and grapefruit juice inhibit CYP3A4 and can increase midazolam levels, leading to prolonged sedation; avoid consumption during therapy. There are no significant interactions with other foods.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Limited data; midazolam is not a known major teratogen but caution advised. Second and third trimesters: May cause fetal respiratory depression, hypotonia, and withdrawal symptoms if used chronically or near term.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Midazolam is excreted into breast milk in small amounts (M/P ratio approximately 0.6). Due to potential for infant sedation and respiratory depression, avoid breastfeeding for at least 24 hours after administration or use with caution.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Increased volume of distribution and clearance in pregnancy may require higher doses for effect; however, due to risk of fetal sedation, use lowest effective dose with careful titration.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Midazolam hydrochloride is a short-acting benzodiazepine used for sedation, anxiolysis, and amnesia. It undergoes extensive hepatic metabolism via CYP3A4; dose reduction is required in hepatic impairment. Paradoxical reactions (e.g., agitation, aggression) can occur, especially in children and elderly. Flumazenil is the reversal agent. Monitor respiratory depression, especially when combined with opioids. Intramuscular injection is an alternative for patients with poor IV access, but absorption is slower. In elderly, reduce dose by 50% due to increased sensitivity. Midazolam is highly protein bound; displacement interactions with valproic acid can increase free fraction.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Midazolam may cause drowsiness, dizziness, and coordination problems; avoid driving or operating machinery for 24 hours after administration.,Alcohol can intensify sedative effects; avoid alcohol for at least 24 hours after use.,Inform your healthcare provider if you are pregnant, breastfeeding, or have a history of drug or alcohol abuse.,You may experience temporary memory loss for events during the procedure; this is a known effect.,Midazolam can cause injection site pain; report any signs of infection or severe discomfort.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIDOZALAM HYDROCHLORIDE vs ACTIQ, answered by our medical review team.
MIDOZALAM HYDROCHLORIDE is a Benzodiazepine that works by Midazolam hydrochloride is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal transmission. This produces sedative, anxiolytic, amnestic, and anticonvulsant effects.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIDOZALAM HYDROCHLORIDE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIDOZALAM HYDROCHLORIDE is: 2.5-10 mg IV bolus for induction; 0.05-0.2 mg/kg/h IV infusion for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) 30-60 min pre-procedure.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIDOZALAM HYDROCHLORIDE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIDOZALAM HYDROCHLORIDE is classified as Category C. First trimester: Limited data; midazolam is not a known major teratogen but caution advised. Second and third trimesters: May cause fetal respiratory depression, hypotonia, and wit. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.